The protective effect of SCR 15-18 on cerebral ischemia-reperfusion injury

Neurological Research

Volumn 33, Issue 8, 2011, Pages 866-874

  Li, Shu ^a   Xian, Jinhong ^b   He, Li ^a   Luo, Xue ^a   Tan, Bing ^a   Yang, Yongtao ^a   Liu, Gaoke ^a   Wang, Zhengqing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral ischemia reperfusion injury; Complement; Protective effect; sCR1; SCR15 18 protein; SCRs 15 18

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT RECEPTOR; MYELOPEROXIDASE; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN SCR[15-18]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PROTECTION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ESCHERICHIA COLI; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN REFOLDING; RAT; REPERFUSION INJURY;

ANIMALS; BRAIN; CEREBRAL INFARCTION; COMPLEMENT ACTIVATION; COMPLEMENT C3B; DISEASE MODELS, ANIMAL; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NEUROPROTECTIVE AGENTS; NEUTROPHILS; PEPTIDE FRAGMENTS; RATS; RECEPTORS, COMPLEMENT; RECOMBINANT PROTEINS; REPERFUSION INJURY;

EID: 80855164480     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132811Y.0000000016     Document Type: Article

References (22)

1. Pan J, Konstas AA, Bateman B, Ortolano GA, Pile-Spellman J. Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. Neuroradiology 2007;49:93-102.
2. Lu F, Chauhan AK, Fernandes SM, Walsh MT, Wagner DD, Davis AE 3rd. The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2008;295:G1042-9.
3. Arumugam TV, Woodruff TM, Lathia JD, Selvaraj PK, Mattson MP, Taylor SM. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009;158:1074-89.
4. Diepenhorst GM, van Gulik TM, Hack CE. Complementmediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg 2009;249:889-99.
5. Mack WJ, Sughrue ME, Ducruet AF, Mocco J, Sosunov SA, Hassid BG, et al. Temporal pattern of C1q deposition after transient focal cerebral ischemia. J Neurosci Res 2006;83:883-9.
6. Van BJ, Bernaudin M, Petit E, Gasque P, Nouvelot A, MacKenzie ET, et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol 2000;161:373-82.
7. Lindsberg PJ, Ohman J, Lehto T, Karjalainen-Lindsberg ML, Paetau A, Wuorimaa T, et al. Complement activation in the central nervous system following bloodbrain barrier damage in man. Ann Neurol 1996;40:587-96.
8. Figueroa E, Gordon LE, Feldhoff PW, Lassiter HA. The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci Lett 2005;380:48-53.
9. Mocco J, Mack WJ, Ducruet AF, King RG, Sughrue ME, Coon AL, et al. Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke. J Neurosurg 2006;105:595-601.
10. Storini C, Rossi E, Marrella V, Distaso M, Veerhuis R, Vergani C, et al. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 2005;19:10-7.
11. Krych-Goldberg M, Atkinson JP. Structure-function relationships of complement receptor type 1. Immunol Rev 2001;180:112-22.
12. Weisman HF, Bartow T, Leppo MK, Marsh HC, Jr, Carson GR, Concino MF et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 1990;249:146-51.
13. von Dobschuetz E, Bleiziffer O, Pahernik S, Dellian M, Hoffmann T, Messmer K. Soluble complement receptor 1 preserves endothelial barrier function and microcirculation in postischemic pancreatitis in the rat. Am J Physiol Gastrointest Liver Physiol 2004;286:G791-6.
14. Krych M, Hauhart R, Atkinson JP. Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem 1998;273:8623-9.
15. Mayer MM. Complement and complement fixation. In: Kabat EA, Mayer MM, editors. Experimental immunochemistry. Springfield, IL: Charles C Thomas; 1961. p. 133-240.
16. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
17. Costa C, Zhao L, Shen Y, Su X, Hao L, Colgan SP, et al. Role of complement component C5 in cerebral ischemia/reperfusion injury. Brain Res 2006;1100:142-51.
18. Rudolph R, Lilie H. In vitro folding of inclusion body proteins. FASEB J 1996;10:49-56.
19. Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 2000;12:1015-23.
20. D'Ambrosio AL, Pinsky DJ, Connolly ES. The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med 2001;7:367-82.
21. Arumugam TV, Tang SC, Lathia JD, Cheng A, Mughal MR, Chigurupati S, et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 2007;104:14104-9.
22. Krych-Goldberg M, Hauhart RE, Porzukowiak T, Atkinson JP. Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors. J Immunol 2005;175:4528-35.